Intellia Therapeutics
NTLA
62 hedge funds and large institutions have $302M invested in Intellia Therapeutics in 2016 Q2 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$140M |
| 2 |
O
OrbiMed
New York
|
+$70.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$28.3M |
| 4 |
Temasek Holdings
Singapore
|
+$21M |
| 5 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$20.3M |
Top Sellers
NTLA Hedge Fund Activity: Q2 2016 in Review
62 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2016, worth a combined $302M.
Buyers outnumbered sellers: 62 funds opened new NTLA positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $140M.
- 62 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $302M of Intellia Therapeutics stock for Q2 2016.
- 62 funds opened new Intellia Therapeutics positions in Q2 2016 and 0 closed out, a net change of +62 holders.
- The largest Intellia Therapeutics buyer in Q2 2016 was Fidelity Investments, an estimated $140M added.
Based on aggregated 13F filings for Q2 2016.